Literature DB >> 26725153

Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.

Thamiris Palacios1, Leland Stillman2, Larry Borish3, Monica Lawrence2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26725153      PMCID： PMC4861669          DOI： 10.1016/j.jaip.2015.11.025

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  Chronic urticaria sera increase basophil CD203c expression.

Authors:  Karen M Yasnowsky; Stephen C Dreskin; Benjamin Efaw; David Schoen; P K Vedanthan; Rafeul Alam; Ronald J Harbeck
Journal:  J Allergy Clin Immunol       Date:  2006-04-27       Impact factor: 10.793

2.  The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals.

Authors:  Emma Guttman-Yassky; Reuven Bergman; Carcom Maor; Merav Mamorsky; Shimon Pollack; Eduardo Shahar
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-01       Impact factor: 6.166

3.  Independent evaluation of a commercial test for "autoimmune" urticaria in normal and chronic urticaria subjects.

Authors:  John A Eckman; Robert G Hamilton; Sarbjit S Saini
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

4.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

Authors:  D W MacGlashan; B S Bochner; D C Adelman; P M Jardieu; A Togias; J McKenzie-White; S A Sterbinsky; R G Hamilton; L M Lichtenstein
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

5.  Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies.

Authors:  John A Eckman; Robert G Hamilton; Laura M Gober; Patricia M Sterba; Sarbjit S Saini
Journal:  J Invest Dermatol       Date:  2008-03-20       Impact factor: 8.551

6.  Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.

Authors:  Lisa A Beck; Gregory V Marcotte; Donald MacGlashan; Alkis Togias; Sarbjit Saini
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

7.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Authors:  Allen Kaplan; Dennis Ledford; Mark Ashby; Janice Canvin; James L Zazzali; Edward Conner; Joachim Veith; Nikhil Kamath; Petra Staubach; Thilo Jakob; Robert G Stirling; Piotr Kuna; William Berger; Marcus Maurer; Karin Rosén
Journal:  J Allergy Clin Immunol       Date:  2013-07       Impact factor: 10.793

8.  Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.

Authors:  Martin Metz; Tatevik Ohanyan; Martin K Church; Marcus Maurer
Journal:  J Dermatol Sci       Date:  2013-09-03       Impact factor: 4.563

9.  IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria?

Authors:  Sabine Altrichter; Hans-Jürgen Peter; Dina Pisarevskaja; Martin Metz; Peter Martus; Marcus Maurer
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240
  9 in total
  12 in total

1.  Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.

Authors:  Matthew D Straesser; Eric Oliver; Thamiris Palacios; Timothy Kyin; James Patrie; Larry Borish; Sarbjit S Saini; Monica G Lawrence
Journal:  J Allergy Clin Immunol Pract       Date:  2017-11-23

Review 2.  Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Authors:  Michael D Tharp; Jonathan A Bernstein; Abhishek Kavati; Benjamin Ortiz; Karen MacDonald; Kris Denhaerynck; Ivo Abraham; Christopher S Lee
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

3.  New insights into the utility of omalizumab.

Authors:  Juan Carlos Cardet; Thomas B Casale
Journal:  J Allergy Clin Immunol       Date:  2019-01-26       Impact factor: 10.793

4.  Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria.

Authors:  R Asero; A V Marzano; S Ferrucci; M Lorini; V Carbonelli; M Cugno
Journal:  Clin Exp Immunol       Date:  2020-03-17       Impact factor: 4.330

5.  The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.

Authors:  Kirti J Johal; Kristin L Chichester; Eric T Oliver; Kelly C Devine; Anja P Bieneman; John T Schroeder; Donald W MacGlashan; Sarbjit S Saini
Journal:  J Allergy Clin Immunol       Date:  2021-03-10       Impact factor: 14.290

Review 6.  Chronic urticaria: a focus on pathogenesis.

Authors:  Riccardo Asero; Alberto Tedeschi; Angelo Valerio Marzano; Massimo Cugno
Journal:  F1000Res       Date:  2017-07-11

7.  Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications.

Authors:  Ilaria Puxeddu; Fiorella Petrelli; Francesca Angelotti; Cristina Croia; Paola Migliorini
Journal:  J Asthma Allergy       Date:  2019-09-20

8.  What Basophil Testing Tells Us About CSU Patients - Results of the CORSA Study.

Authors:  João Marcelino; Katrine Baumann; Per Stahl Skov; Maria Conceição Pereira Santos; Inga Wyroslak; Jörg Scheffel; Sabine Altrichter; Anders Woetmann; Manuel Pereira-Barbosa; Célia Costa; Marcus Maurer
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

9.  Omalizumab for chronic urticaria in Latin America.

Authors:  Paul Wilches; Paola Wilches; Juan Carlos Calderon; Annia Cherrez; Ivan Cherrez Ojeda
Journal:  World Allergy Organ J       Date:  2016-11-23       Impact factor: 4.084

10.  Relationship between changes in the 7-day urticaria activity score after treatment with omalizumab and the responsiveness of basophils to FcεRI stimulation in patients with chronic spontaneous urticaria.

Authors:  Takahiro Endo; Shota Toyoshima; Koremasa Hayama; Maho Tagui; Yusuke Niwa; Mana Ito; Tadashi Terui; Yoshimichi Okayama
Journal:  Asia Pac Allergy       Date:  2020-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.